Clearmind Medicine Inc. (CMND)
NASDAQ: CMND · Real-Time Price · USD
2.230
+0.060 (2.76%)
At close: Feb 2, 2026, 4:00 PM EST
2.370
+0.140 (6.28%)
After-hours: Feb 2, 2026, 7:59 PM EST

Clearmind Medicine Income Statement

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Selling, General & Admin
3.614.364.763.172.44
Research & Development
2.061.381.543.080.52
Operating Expenses
5.675.746.36.252.97
Operating Income
-5.67-5.74-6.3-6.25-2.97
Interest Expense
-0.02-0.04-0.01-0.01-
Interest & Investment Income
0.130.270.09--
Currency Exchange Gain (Loss)
0-0.01-0.08-0-0.03
Other Non Operating Income (Expenses)
1.130.71-2.19-0.29-
EBT Excluding Unusual Items
-4.42-4.81-8.5-6.56-3
Gain (Loss) on Sale of Investments
0.84-0.07-0.11-0.31-
Other Unusual Items
-0.21----
Pretax Income
-3.79-4.88-8.6-6.87-3
Income Tax Expense
0.070.380.020.03-
Net Income
-3.86-5.25-8.62-6.89-3
Net Income to Common
-3.86-5.25-8.62-6.89-3
Shares Outstanding (Basic)
00---
Shares Outstanding (Diluted)
00---
Shares Change (YoY)
63.98%----
EPS (Basic)
-30.35-67.80---
EPS (Diluted)
-30.35-67.80---
Free Cash Flow
-4.73-4.86-6.3-3.73-2.31
Free Cash Flow Per Share
-37.25-62.69---
EBITDA
-5.66-5.73-6.28-6.23-2.96
D&A For EBITDA
0.010.010.020.020.01
EBIT
-5.67-5.74-6.3-6.25-2.97
Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q